How to Write a Grant Appeal Letter: NIH Grounds, Process, and Odds

A grant appeal is a narrow, procedural mechanism — not a second chance to argue the science. At NIH, the only funder with a fully codified, public appeal policy, an appeal letter can challenge a specific flaw in how an application was reviewed; it cannot challenge the reviewers’ scientific judgment, the resulting priority score, or the funding decision itself. Confusing the two is the single most common — and most consequential — mistake a research administrator sees a first-time appellant make, because it wastes the one procedural remedy available on a request that was never eligible for it in the first place.

This guide covers what is actually appealable under NIH policy, who can file, the timeline and process, how to structure the letter itself, how NSF’s comparable process differs, and — the part administrators most need to say out loud to faculty — why appeals succeed rarely and resubmission is usually the more productive path.

What a Grant Appeal Actually Is — and What It Isn’t

Per the NIH Grants Policy Statement, section 2.4.2, NIH’s appeal system exists “to preserve and underscore the fairness of the NIH peer review process” by giving applicants a way to seek reconsideration when they believe the review itself — not its conclusion — was procedurally flawed. The policy is explicit about its own limits: it does not apply to appeals of NIH funding decisions, appeals of the technical evaluation of research and development contract proposals, or appeals of decisions concerning MERIT award extensions. A funding decision made after a valid, unbiased review — even one you believe reached the wrong conclusion — is not an appealable event.

This is the distinction that trips people up: an appeal contests the integrity of the process (was a reviewer conflicted, unqualified, or biased; did a reviewer get a fact wrong that mattered), not the outcome of a process that ran correctly. A well-run but unfavorable review is not grounds for appeal, however strongly the applicant disagrees with it.

NIH’s Four Allowable Grounds for Appeal

An appeal letter is accepted only if it is based on one or more of four specific issues, set out in the NIH Grants Policy Statement and reaffirmed in NOT-OD-11-064:

1. Evidence of bias on the part of one or more peer reviewers.
2. Conflict of interest on the part of one or more non-federal peer reviewers, as defined at 42 CFR §52h.5 — broadly, a reviewer who received or could receive a direct financial benefit from the application under review, or a financial benefit exceeding $10,000/year in aggregate from the applicant institution or PI.
3. Lack of appropriate expertise within the Scientific Review Group (SRG) convened to review the application.
4. Factual error(s) made by one or more reviewers that could have substantially altered the outcome of review.

Just as important is what is explicitly not an acceptable basis. NIH guidance is direct on this point: “Appeal letters based solely on differences of scientific opinion will not be accepted.” Beyond that core exclusion, appeals also cannot rest on new material not in the original submission, a prior application version, dissatisfaction with the review location or panel logistics, complaints about a cover letter, or — per the scope limits above — applications submitted to a specific Request for Applications (RFA) competition, which typically fall outside this general policy and may have their own IC-specific review terms. See CASRAI’s NIH RFA guide for how RFA review differs from standard study-section review in the first place.

Who Files, and the AOR Concurrence Requirement

An appeal letter is not something a PI submits alone. It requires the concurrence of the applicant organization’s Authorized Organizational Representative (AOR) — typically the institution’s sponsored programs or research administration office — co-signing alongside the PD/PI. NIH policy is explicit that a letter lacking AOR concurrence is not treated as a valid appeal at all; it is logged as a grievance instead, a different and less formal category that does not trigger the Advisory Council review process described below.

In practice, this makes the research administrator a gatekeeper, not just a co-signer: before adding institutional concurrence, confirm the letter actually states one or more of the four allowable grounds, with specific, evidence-based reference to the summary statement — not a rebuttal of the scientific critique dressed up in procedural language.

The NIH Appeal Timeline and Review Process

The process runs on a fixed sequence tied to the Institute or Center’s (IC’s) Advisory Council or Board meeting cycle:

1. Summary statement issued. An appeal can only be filed after the summary statement documenting the initial review is available — the letter has to cite specifics from it, not a general impression of the review.
2. Letter submitted to the IC. The AOR- and PD/PI-signed letter goes to the Program Official at the awarding IC, generally well before the closed session of the Advisory Council meeting to which the application is assigned — exact lead times are set by each IC’s program office, so confirm the specific IC’s deadline rather than assuming a single NIH-wide number.
3. IC staff screen the letter. Senior IC staff first determine whether the letter meets the formal criteria for a valid appeal (AOR concurrence, one of the four grounds, timing) before it goes any further.
4. Advisory Council or Board considers it. The relevant Council reviews the appeal alongside the summary statement and either concurs with the original review outcome or recommends the application be re-reviewed.
5. Re-review, if recommended. The original application is re-reviewed without new material or modifications — the applicant does not get to revise the application as part of an appeal. It may go to the same or a different SRG depending on the nature of the flaw.
6. Final. The Council’s decision on the appeal is final, and the outcome of any resulting re-review cannot itself be appealed again.

One consequence that catches applicants off guard: NIH treats an application with a pending appeal as still “pending initial peer review.” Per NOT-OD-11-101, NIH will not review a resubmission (A1) of the same project while an appeal of the original (A0) application is unresolved — if both exist at once, the applicant organization must choose, in writing with AOR concurrence, to withdraw one or the other. Filing an appeal is not a cost-free parallel option alongside resubmission; it can actively delay the resubmission path while it’s pending.

How to Structure a Grant Appeal Letter

An effective appeal letter is short, procedural, and evidence-anchored — the opposite of a rebuttal to the scientific critique. It should generally include:

• Routing information — application/grant number, PD/PI name, awarding IC, funding opportunity number, and the review round or Council cycle in question.
• A clear statement of which of the four grounds applies — named explicitly (bias, conflict of interest, lack of expertise, or factual error), not implied.
• Specific, citable evidence from the summary statement — the exact critique, reviewer comment, or panel-composition fact the appeal turns on. Vague dissatisfaction is not evidence.
• No re-litigation of the science. Anything that reads as “the reviewers were wrong about the merit of the approach” rather than “the review process itself was flawed in this specific, procedural way” undermines the letter’s own eligibility.
• A requested remedy — ordinarily, re-review of the unmodified application by an appropriately constituted panel.
• AOR concurrence and signature, alongside the PD/PI’s.

Program Officials are a resource here, not just a mail slot: NIH institutes consistently advise applicants to discuss the summary statement with their assigned Program Officer before drafting an appeal — often the concern is resolvable through that conversation, or the Program Officer can confirm early whether the concern plausibly fits one of the four grounds before institutional time goes into a letter that won’t be accepted.

NSF and Other Funders: Terms and Grounds Differ

NIH’s narrow, procedure-only appeal policy is not the industry standard — it’s specific to NIH, and a research administrator advising faculty across multiple funders needs to keep the processes separate. NSF, for example, calls its comparable mechanism reconsideration, governed by PAPPG Chapter IV.D, and it is meaningfully broader: NSF states the aim of reconsideration is to ensure review was “fair and reasonable, both substantively and procedurally” — meaning scientific and technical merit genuinely can be examined, within the context of budget availability and program priorities, alongside procedural issues like undisclosed conflicts of interest. NSF also requires an informal step first: the PI must contact the cognizant Program Officer or Division Director for clarification before a formal written reconsideration request is even considered, and that request goes to the Assistant Director or Office Head for the relevant Directorate. NSF is explicit that reconsideration is not an adversarial process, no formal hearing is provided, and an award is not guaranteed even where an error in the initial review is established — and proposals declined for purely administrative or financial reasons aren’t eligible for reconsideration at all.

The practical takeaway: never assume one funder’s appeal terminology, grounds, or procedure carries over to another. Check the specific funder’s current policy guide — the CASRAI’s NIH Grants overview for NIH mechanisms generally, the PAPPG for NSF, and the individual agency’s own guide for anything funded under the Uniform Guidance baseline — before advising a faculty member on what’s actually available to them.

Why Appeals Rarely Succeed — and Resubmission Is Usually the Better Path

This is the point research administrators most need to make plainly, even when it’s not what a disappointed PI wants to hear. The four NIH grounds are deliberately narrow by design, and the large majority of unfunded-application frustration is a disagreement with the scientific conclusion — which, categorically, is not appealable no matter how strongly held or how the letter is worded. An appeal that doesn’t genuinely fit one of the four grounds will not be accepted as a valid appeal at all; at best it becomes a grievance with no Council-level review attached.

Even a technically valid, successful appeal doesn’t produce funding — its ceiling is a re-review at a later Council cycle, with no new material and no guarantee of a better outcome, and that re-review’s result is itself final and unappealable. Meanwhile, as covered above, an unresolved appeal can block NIH from accepting a resubmission of the same project in the interim.

Resubmission, by contrast, is built specifically to engage the substantive critique. NIH allows a single resubmission (A1) per original application, addressed directly to the reviewers’ actual comments in the summary statement. And the path doesn’t end even if the A1 is also unfunded: since NOT-OD-14-074 (2014), an applicant may submit the same project as a new A0 application for a later cycle without having to demonstrate a substantial change in scientific direction — meaning an unfunded resubmission is not a dead end for a project the study section otherwise found meritorious.

The working rule of thumb: default to resubmission. Reserve an appeal for the genuinely rare case where there is specific, citable evidence of a procedural flaw — a documented conflict of interest, a factual error a reviewer can be shown to have made, or a panel that plainly lacked the relevant expertise — not for “I disagree with the score.”

A Practical Checklist for Research Administrators Advising Faculty

• Read the summary statement together before drafting anything — confirm what, specifically, the critique says.
• Test the complaint against the four allowable grounds explicitly. If it doesn’t map to bias, conflict of interest, lack of expertise, or a substantive factual error, it is not appeal material.
• Contact the assigned Program Officer first — often the fastest way to get a real answer, and to confirm eligibility before committing institutional time.
• Confirm this isn’t an RFA-specific application, which generally falls outside this policy and may have separate IC-specific review terms.
• Check the IC’s deadline relative to the relevant Advisory Council meeting — appeals are time-bound to that cycle.
• Weigh the resubmission trade-off explicitly: does filing the appeal risk delaying an A1 the applicant could otherwise submit now?
• If the grounds are genuinely met, route the AOR concurrence signature promptly — a valid appeal without institutional concurrence is only a grievance.
• In the far more common case, redirect energy toward a strong resubmission (or, per NOT-OD-14-074, a fresh A0 if the A1 is also unsuccessful) rather than a procedural challenge unlikely to be accepted.

Frequently Asked Questions

Can I appeal my NIH priority score or percentile?

No. The priority score and percentile are the outcome of the scientific review, not a procedural artifact — appeals challenge how the review was conducted, not the conclusion it reached. Disagreement with the score, on its own, is explicitly excluded as a basis for appeal.

What’s the difference between an NIH appeal and a grievance?

An appeal is a formal request, co-signed by the PD/PI and the institution’s AOR, that states one of the four allowable procedural grounds and is reviewed by the assigned Advisory Council. A letter that lacks AOR concurrence, or that doesn’t fit one of the four grounds, is logged as a grievance instead — a less formal category that does not go through the Council-level appeal review process.

Can I appeal an application submitted to an RFA?

Generally no — NIH’s general appeal policy does not apply to applications reviewed under a specific Request for Applications competition. RFA review is convened and administered by the issuing Institute or Center for that one-time competition, and any avenue for raising a concern is typically handled through that IC directly rather than the standard appeal policy. Confirm with the IC’s program staff for the specific RFA in question.

Does filing an appeal stop me from resubmitting?

It can. NIH treats an application with a pending appeal as still “pending initial peer review,” and per NOT-OD-11-101 will not review a resubmission (A1) of the same project while that appeal is unresolved. If both an appeal and a resubmission exist for the same project at once, the applicant organization has to choose, in writing with AOR concurrence, which one to withdraw.

Who has to sign an NIH grant appeal letter?

Both the PD/PI and the applicant organization’s Authorized Organizational Representative (AOR) — typically the institution’s sponsored programs office. Concurrence from the AOR is a formal requirement; without it, NIH does not treat the letter as a valid appeal.

Does NSF use the same appeal process as NIH?

No. NSF’s comparable process, called reconsideration under PAPPG Chapter IV.D, is broader than NIH’s — it can examine scientific and technical merit as well as procedural issues, requires an informal conversation with the Program Officer or Division Director before a formal written request, and is decided by the relevant Assistant Director or Office Head rather than an Advisory Council. Always check the specific funder’s own policy rather than assuming NIH’s narrower rules apply elsewhere.

Where to Go Deeper

For the broader NIH funding-mechanism and review context this guide sits inside, see CASRAI’s NIH Grants: An Overview, NIH RFA (Request for Applications), and Peer Review guides. For the surrounding pre-award and compliance picture, see Letter of Support for a Grant Proposal and Federal Grant Compliance Checklist. For the full grants-management landscape, see the Grants Management & Research Funding cluster page.